MindBio Therapeutics Corp. (MBIO) — MindBio Therapeutics shared results from its 89-patient Phase 2b trial of repeated take-home microdosed LSD (MB22001) in major depressive disorder, which failed to demonstrate superiority over placebo.
The disappointing readout — described by industry observers as the collapse of the largest LSD microdosing program to date — raised fresh questions about the therapeutic value of microdosing relative to full-dose psychedelic approaches being pursued by peers.
Source: thenewswire.com
For the rest of that week's sector news, read our week in review.